Authors concluded that the CAF-derived SPP1 blockade might be a potential therapeutic target to alleviate TKI resistance in HCC treatment, whereas measurement of the plasma SPP1 level before TKI chemotherapy might predict responses to the planned treatment [98]. The gene discussed is SPP1; the disease is hepatocellular carcinoma.